The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia

by Rauzan M., Chuah C.T.H., Ko T.K., Tiong Ong S.
Published 2020

BIM Deletion Polymorphism Profiling Complements Prognostic Values of Risk Scores in Imatinib-treated Asian Chronic Myeloid Leukemia Patients

by Hein Than, Weng Kit Lye, Colin Sng, John Allen, S., Tiong Ong, Charles Chuah
Published 2019

Identification of drugs for leukaemia differentiation therapy by network pharmacology

by Eleni G Christodoulou, Lin Ming Lee, Kian Leong Lee, Tsz Kan Fung, Eric So, Enrico Petretto, S. Tiong Ong, Owen JL Rackham
Published 2020